Kiadis Pharma B.V.
Kiadis Pharma B.V. (Kiadis) is a pharmaceutical company that is engaged in the development of oncological products to eliminate the transplantation risk. The company's product pipeline includes, ATIR that eliminates the alloreactive T-cells from mismatched donor transplants and is under development to prevent acute Graft versus Host Disease (GvHD), Reviroc is designed to specifically eliminate cancer cells from transplants for autologous transplantations and Rhitol eliminates the patients' auto reactive immune cells thus enabling in treatment of steroid refractory chronic graft versus host disease (GvHD). The company's key focus area is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis is headquartered in Amsterdam, Netherlands.